Mechanism of the inhibition of leukemia cell growth and induction of apoptosis through the activation of ATR and PTEN by the topoisomerase inhibitor 3EZ, 20Ac-ingenol

Leukemia Research

Volumn 39, Issue 9, 2015, Pages 927-932

  Miyata, Shohei ^a   Fukuda, Yasuaki ^a   Tojima, Haruka ^a   Matsuzaki, Keiichi ^a   Kitanaka, Susumu ^a   Sawada, Hiroshi ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Apoptosis; ATM ATR; Inhibition of proliferation; P53; PTEN Akt; Topo catalytic inhibitor

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CASPASE 3; DNA TOPOISOMERASE INHIBITOR; HISTONE GAMMA H2AX; HISTONE H2AX; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; [3 O (2',4' DECADIENOYL) 20 O ACETYLINGENOL]; ANTINEOPLASTIC AGENT; ATM PROTEIN, HUMAN; ATR PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DITERPENE; H2AFX PROTEIN, HUMAN; HISTONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHROMOSOME STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA BALL 1 CELL LINE; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; UPREGULATION; AGONISTS; CELL CYCLE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DITERPENES; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HUMANS; LEUKEMIA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOPOISOMERASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940959283     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.06.006     Document Type: Review

References (50)

1. Xu N., Lao Y., Zhang Y., Gillespie D.A. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol. 2012, 2012:1-15.
2. Stiles B., Groszer M., Wang S., Jiao J., Wu H. PTENless means more. Dev. Biol. 2004, 273:175-184. Review.
3. Ming M., He Y.Y. PTEN in DNA damage repair. Cancer Lett. 2012, 319:125-129.
4. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., Wu H., Li L. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.
5. Levy D.S., Kahana J.A., Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009, 113:1723-1729.
6. Huang F.F., Wu D.S., Zhang L., Yu Y.H., Yuan X.Y., Li W.J., Chen X.P., Zhao X.L., Chen F.P., Zeng H. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett. 2013, 336:96-105.
7. Matsuoka Y., Nagahara Y., Ikekita M., Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 2003, 138:1303-1312.
8. Peng C., Chen Y., Yang Z., Zhang H., Osterby L., Rosmarin A.G., Li S. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010, 115:626-635.
9. Selvendiran K., Tong L., Vishwanath S., Bratasz A., Trigg N.J., Kutala V.K., Hideg K., Kuppusamy P. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J. Biol. Chem. 2007, 282:28609-28618.
10. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168. Review.
11. Cliby W.A., Lewis K.A., Lilly K.K., Kaufmann S.H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 2002, 277:1599-1606.
12. Pommier Y., Barcelo J.M., Rao V.A., Sordet O., Jobson A.G., Thibaut L., Miao Z.H., Seiler J.A., Zhang H., Marchand C., Agama K., Nitiss J.L., Redon C. Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81:179-229. Review.
13. Furuta T., Takemura H., Liao Z.Y., Aune G.J., Redon C., Sedelnikova O.A., Pilch D.R., Rogakou E.P., Celeste A., Chen H.T., Nussenzweig A., Aladjem M.I., Bonner W.M., Pommier Y. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 2003, 278:20303-20312.
14. Pilch D.R., Sedelnikova O.A., Redon C., Celeste A., Nussenzweig A., Bonner W.M. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem. Cell Biol. 2003, 81:123-129. Review.
15. Andoh T., Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta 1998, 1400:155-171. Review.
16. Capranico G., Marinello J., Baranello L. Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity. Biochim. Biophys. Acta 2010, 1806:240-250.
17. Wu N., Wu X.W., Agama K., Pommier Y., Du J., Li D., Gu L.Q., Huang Z.S., An L.K. A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells. Biochemistry 2010, 49:10131-10136.
18. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802. Review.
19. Deming P.B., Cistulli C.A., Zhao H., Graves P.R., Piwnica-Worms H., Paules R.S., Downes C.S., Kaufmann W.K. The human decatenation checkpoint. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12044-12049.
20. Park I., Avraham H.K. Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1. Exp. Cell Res. 2006, 312:1996-2008.
21. Wang L., Roy S.K., Eastmond D.A. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells. Mutat. Res. 2007, 616:70-82.
22. Luo K., Yuan J., Chen J., Lou Z. Topoisomerase IIalpha controls the decatenation checkpoint. Nat. Cell Biol. 2009, 11:204-210.
23. Robinson H.M., Bratlie-Thoresen S., Brown R., Gillespie D.A. Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193. Cell Cycle 2007, 6:1265-1267.
24. Fukuda Y., Kanbe M., Watanabe M., Dan K., Matsuzaki K., Kitanaka S., Miyata S. 3EZ, 20Ac-ingenol, a catalytic inhibitor of topoisomerases, downregulates p-Akt and induces DSBs and apoptosis of DT40 cells. Arch. Pharm. Res. 2013, 36:1029-1038.
25. Kanbe K., Fukuda Y., Watanabe M., Matsuzaki K., Kitanaka S., Miyata S. Hypersensitive inhibition of the proliferation of cells with mutated DNA repair-related genes by the catalytic topoisomerase II inhibitor 20-O-ingenolEZ. Pharmacol. Pharm. 2012, 3:158-165.
26. Hlobilkova A., Knillova J., Svachova M., Skypalova P., Krystof V., Kolar Z. Tumour suppressor PTEN regulates cell cycle and protein kinase B/Akt pathway in breast cancer cells. Anticancer Res. 2006, 26:1015-1022.
27. Redondo-Muñoz J., Escobar-Díaz E., Hernández Del Cerro M., Pandiella A., Terol M.J., García-Marco J.A., García-Pardo A. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin. Cancer Res. 2010, 16:4382-4391.
28. Zhang X.H., Feng R., Lv M., Jiang Q., Zhu H.H., Qing Y.Z., Bao J.L., Huang X.J., Zheng X.L. Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway. Leuk. Res. 2013, 37:1719-1725.
29. West K.A., Castillo S.S., Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 2002, 5:234-248. Review.
30. Nakashio A., Fujita N., Rokudai S., Sato S., Tsuruo T. Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 2000, 60:5303-5309.
31. Liu Y., Xing H., Weng D., Song X., Qin X., Xia X., Weng Y., Liang F., Chen G., Han X., Ma X., Wang S., Zhou J., Xu G., Meng L., Ma D. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Cancer Lett. 2009, 274:47-53.
32. Zhao Z., Wang J., Tang J., Liu X., Zhong Q., Wang F., Hu W., Yuan Z., Nie C., Wei Y. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem. J. 2012, 444:291-301.
33. Yu H.Y., Kim S.O., Jin C.Y., Kim G.Y., Kim W.J., Yoo Y.H., Choi Y.H. β-lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway. Biomol. Ther. 2014, 22:184-192.
34. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
35. Adachi N., Suzuki H., Iiizumi S., Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J. Biol. Chem. 2003, 278:35897-35902.
36. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
37. Fernandez-Capetillo O., Chen H.T., Celeste A., Ward I., Romanienko P.J., Morales J.C., Naka K., Xia Z., Camerini-Otero R.D., Motoyama N., Carpenter P.B., Bonner W.M., Chen J., Nussenzweig A. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat. Cell Biol. 2002, 4:993-997.
38. Bower J.J., Zhou Y., Zhou T., Simpson D.A., Arlander S.J., Paules R.S., Cordeiro-Stone M., Kaufmann W.K. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM. Cell Cycle 2010, 9:1617-1628.
39. Pastor N., Domínguez I., Orta M.L., Campanella C., Mateos S., Cortés F. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat. Res. 2012, 738-739:45-51.
40. Kryeziu K., Jungwirth U., Hoda M.A., Ferk F., Knasmüller S., Karnthaler-Benbakka C., Kowol C.R., Berger W., Heffeter P. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther. 2013, 12:1073-1084.
41. Hu Y.C., Hsieh B.S., Cheng H.L., Huang L.W., Huang T.C., Huang I.Y., Chang K.L. Osteoblasts survive the arsenic trioxide treatment by activation of ATM-mediated pathway. Biochem. Pharmacol. 2013, 85:1018-1026.
42. Sordet O., Liao Z., Liu H., Antony S., Stevens E.V., Kohlhagen G., Fu H., Pommier Y. Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. J. Biol. Chem. 2004, 279:33968-33975.
43. Sordet O., Goldman A., Pommier Y. Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes. Mol. Cancer Ther. 2006, 5:3139-3144.
44. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H., Zhang P., Dobrowolski S., Bai C., Connell-Crowley L., Swindell E., Fox M.P., Wei N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 1995, 6:387-400.
45. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
46. Moll U.M., Wolff S., Speidel D., Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Chem. Biol. 2005, 17:631-636. Review.
47. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., Masuyama N., Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 2002, 277:21843-21850.
48. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 2002, 277:5484-5489.
49. Martin S.A., Ouchi T. Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN. Mol Cancer Ther. 2008, 7:2509-2516.
50. Shin S.Y., Yong Y., Kim C.G., Lee Y.H., Lim Y. Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in HeLa cells. Cancer Lett. 2010, 287:231-239.